Cryopyrin-associated Periodic Syndromes (CAPS)

Also known as: Cryopyrin Associated Periodic Syndrome / Cryopyrin-Associated Periodic Syndrome / Cryopyrin-Associated Periodic Syndromes / Cryopyrin associated periodic syndrome (disorder) / Chronic infantile neurological cutaneous and articular syndrome / CINCA syndrome / Chronic infantile neurological, cutaneous and articular syndrome (disorder) / Neonatal-onset multisystemic inflammatory disease / NOMID / Chronic Infantile Neurological, Cutaneous, and Articular Syndrome / Familial Cold Autoinflammatory Syndrome / FCAS / Familial cold urticaria (disorder) / Familial cold urticaria / Muckle-Wells Syndrome / Familial amyloid nephropathy with urticaria AND deafness (disorder)

DrugDrug NameDrug Description
DB00026AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).
DB06168CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
DB06372RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
DrugDrug NamePhaseStatusCount
DB00026AnakinraNot AvailableCompleted1